Molecular mass of semaglutide and why the figure differs between sources — does this still hold? posts 31–60

The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the acylation is another. Different sources emphasise different details.

It is the kind of thing that is obvious once and never again.

The arithmetic in post #31 is right; the assumption feeding it is the part to check.

The most useful thing anyone has posted about Molecular mass of semaglutide in this category was a table of what had been measured and by whom. That is what I would want again.

Post #31 put the caveat in the right place and I want to underline it.

Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the dosing schedule, which admits expectation effects. Weekly versus daily itself is part of the comparison, not a confounding variable to be removed.

That much is documented. The rest is how I have interpreted it.

Adding a data point of agreement rather than a data point.

The STEP programme populations were selected: enrollment criteria required baseline body mass index over 30, no recent blood pressure crisis, no recent retinopathy, no renal disease at the time. Applying results from that population to someone well outside it is an extrapolation and should be called one.

The oral formulation is a genuinely different pharmaceutical problem from the injectable and shares only the active molecule. Absorption enhancers, fasting requirements and a very different bioavailability mean dose numbers do not translate between the two at all.

Post #35 and I disagree about the size of the effect, not about the direction.

Adding a null result on Molecular mass of semaglutide. I looked, carefully, and found nothing, and null results deserve posting precisely because they never are.

Taking post #35 at face value and following it one step further.

The C-cell question: semaglutide triggered medullary thyroid carcinoma in rodent toxicology studies. A signal in rodents does not automatically appear in humans, but it is the reason the compound is contraindicated in people with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

That is the honest state of it as of this week.

Source for the Molecular mass of semaglutide figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the paper is.

Reading the surrounding paragraph is worth the two minutes. The authors are more careful than their summarisers.

The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice. Visible particles or frank cloudiness is different and would be reason to contact the supplier.

Post #40 is right about the mechanism and I think understates the practical bit.

Reframing Molecular mass of semaglutide slightly, because I think the disagreement is about the question rather than the answer. If the question is "does it happen", yes. If it is "how often", nobody here knows.

Coming back to post #38, because the follow-up matters more than the original answer.

On dose steps: the four-week interval in the pivotal programme was a trial design choice, and slower escalation was not studied. That means the evidence supports not going faster and says nothing at all about going slower.

For what it is worth, the same held on the two occasions I checked.

Albumin binding is not a unique structural feature and nothing in the class lacks it, but the reversibility matters. Semaglutide binds albumin covalently through a fatty side chain, which creates a very long half-life at the cost of sequestering the free form. That is a trade-off and it is the trade-off that allows weekly dosing.

On alcohol: the labelling does not contraindicate it, but it raises gastric irritation risk and semaglutide already does that. There is no published interaction study and the conservative position is to limit it if you are titrating or if gastrointestinal symptoms are troublesome.

Worth checking against a second source before it gets quoted onward.